Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 7Recurrence 5Leukemia, Myeloid, Acute 5Glioblastoma 4Colorectal Neoplasms 3Neoplasms, Plasma Cell 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioma 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Sarcoma 1Richter's Transformation 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

fludarabine phosphate 23Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 18Mycophenolic Acid 16Cyclophosphamide 15Busulfan 15Tacrolimus 14Antilymphocyte Serum 14Cyclosporine 11Melphalan 10Rituximab 9Methotrexate 9Etoposide 8romidepsin 6Flow Cytometry 6Filgrastim 6Vorinostat 5Dexamethasone 5thymoglobulin 4fludarabine 4Sirolimus 4Granulocyte Colony-Stimulating Factor 4Carboplatin 4Calcium Dobesilate 4Bexarotene 4Alemtuzumab 4Thiotepa 3Therapeutics 3Radiotherapy 3Panobinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Cutaneous × selinexor × Clear all
NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
286 enrolled 26 charts
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02314247 2023-01-26

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2 Terminated
16 enrolled 16 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡